Mon, Sep 1, 2014, 6:37 PM EDT - U.S. Markets closed for Labor Day


% | $
Quotes you view appear here for quick access.

BioTime, Inc. Message Board

  • drwestclone drwestclone Feb 13, 2013 3:38 PM Flag

    Biotime/LifeMap/Celera/Quest Diagnostics

    Let's put this LifeMap thing in context:

    In the late 1990's Celera was the main contributor to cutting edge science for the 'Genome Project'. In 2011 Celera was bought for 344 MIL by Quest Diagnostics. At the time there was a conflict in that The NIH and contributors on the project basically said that genes couldn't be patented. This obviously is not in question since stem cell lines can be patented.

    Biotime's LifeMap is possibly along the same lines following in Celera's foot steps. Biotime's mapping of the embryome, bio informatics and human disease is in many ways just as important as the initial genome mapping project.Nobody has such extensive inclusive database that i am aware of, and nobody has the body hESC lines Biotime has. Certainly the gold standard and when scientists need a reference, this will be it.

    Now the question is money. Will LifeMap be able to make sufficient revenue on worldwide subscriptions of their databases? Revenue will surely increase but this is not the point here, one has to look at the big picture. By acquiring Lifemaps Biotime has now has the vehicle for presenting their products. Biotime behind the scenes has been patenting every hESC progenitor cells that exists in the body.

    LifeMap IPO in a year or two will give Biotime the option to sell. Depends on which focus they want to be their bread and butter. OncoCyte(Cancer/cancer detection)? LifeMaps?, ReCyte? OrthoCyte?

    As these subsidiaries grow, the option to sell one becomes a reality giving BTX the $ needed to continue on alone without sharing profits with big pharma.

    2013 lookin good!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Good post! Interesting comparison.

    • let's put your post in context:

      1. celera had a PIPELINE with drugs ACTUALLY in FDA Trials.

      2. NONE of biotime's so-called "hESC progenitor cells" have been shown to exist in the human body -- remember, all these "progenitor" cells have been made in vitro: they are lab-created inventions - Frankencells. NONE are ready for human therapies.

      3. it is simply not possible that any of biotime's "subsidiaries" would successfully IPO ~ for that you need a market.

      the MOST wonderful thing about science is that it is based on fact ~ truth does not (cannot) stay hidden for long.


      • 1 Reply to drwestclown
      • baltbear Feb 13, 2013 6:14 PM Flag

        let's put it into equity context: the #$%$-think of patenting genes that was opposed some years ago has been opposed bu the European High Court, resulting in gern taking i/p into which it had put well over $160mm, rolling it up into a small red pill and getting btx to swallow for $5mm.
        Because there was now somebody who came to btx becuase of their addiction to that kind of small red pill.

3.11+0.13(+4.36%)Aug 29 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Criteo SA
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT
Yahoo! Inc.
NasdaqGSFri, Aug 29, 2014 4:00 PM EDT